Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

GL Partners Adds to Position in SciClone Pharmaceuticals; Reveals New Stake in China Biologic Products

GL Partners Capital Management has increased the holding of SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) stock. In a recent filing with the Securities and Exchange Commission, the fund has revealed that it now holds 3.7 million shares of SciClone Pharmaceuticals, up from the previously reported 3.3 million. GL Partners’ current position accounts for 7.1% of the company’s outstanding shares. The fund has also reported opening a position in China Biologic Products Inc (NASDAQ:CBPO).

SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN)SciClone Pharmaceuticals provides therapy solutions for a number of disorders, both in People’s Republic of China and internationally. Company shares have registered a significant rally in July and, following the top in the beginning of August, have fallen back to the level they traded at in January. At the moment, shares change hands at a price of $4.66 and have a trailing Price to Earnings (P/E) ratio of 20.26. The forward P/E ratio of 8.59 suggests market participants expect the company to improve it’s financial performance. In the third quarter of 2013, SciClone Pharmaceuticals registered revenues of $35 million and earnings per share of $0.16. Analysts expect the share price to bounce back, having set a mean target of $8 apiece.

China Biologic Products

GL Partners has also initiated a passive position in China Biologic Products.  The fund has acquired a little under 1.5 million shares of the biopharmaceutical company, which represents 5.8% of the common stock.

China Biologic’s stock has rallied 99% in 2013, with shares currently trading at $29.35. The stock has a trailing P/E ratio of 15.69 and does not pay a dividend. For the third quarter of 2013, China Biologic Products has reported revenues of $53 million and earnings per diluted share of $0.53. Analysts expect a weaker financial performance in the current quarter, forecasting revenues of $41.5 million and earnings per share of $0.38.

Disclosure: none

Recommended reading:

Hedge Fund News: Kyle Bass, Edward Lampert & David Tepper

Brown Trout Management Reveals New Stake in Camco Financial Corp.

Becker Drapkin Management Decreases Stake in Pixelworks

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
This is a FREE report from Insider Monkey. Credit Card is NOT required.